Literature DB >> 20724638

mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists.

Nanxin Li1, Boyoung Lee, Rong-Jian Liu, Mounira Banasr, Jason M Dwyer, Masaaki Iwata, Xiao-Yuan Li, George Aghajanian, Ronald S Duman.   

Abstract

The rapid antidepressant response after ketamine administration in treatment-resistant depressed patients suggests a possible new approach for treating mood disorders compared to the weeks or months required for standard medications. However, the mechanisms underlying this action of ketamine [a glutamate N-methyl-D-aspartic acid (NMDA) receptor antagonist] have not been identified. We observed that ketamine rapidly activated the mammalian target of rapamycin (mTOR) pathway, leading to increased synaptic signaling proteins and increased number and function of new spine synapses in the prefrontal cortex of rats. Moreover, blockade of mTOR signaling completely blocked ketamine induction of synaptogenesis and behavioral responses in models of depression. Our results demonstrate that these effects of ketamine are opposite to the synaptic deficits that result from exposure to stress and could contribute to the fast antidepressant actions of ketamine.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20724638      PMCID: PMC3116441          DOI: 10.1126/science.1190287

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  14 in total

1.  Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.

Authors:  Madhukar H Trivedi; A John Rush; Stephen R Wisniewski; Andrew A Nierenberg; Diane Warden; Louise Ritz; Grayson Norquist; Robert H Howland; Barry Lebowitz; Patrick J McGrath; Kathy Shores-Wilson; Melanie M Biggs; G K Balasubramani; Maurizio Fava
Journal:  Am J Psychiatry       Date:  2006-01       Impact factor: 18.112

2.  Ketamine and the potential role for rapid-acting antidepressant medications.

Authors:  John H Krystal
Journal:  Swiss Med Wkly       Date:  2007-04-21       Impact factor: 2.193

Review 3.  The glutamate synapse in neuropsychiatric disorders. Focus on schizophrenia and Alzheimer's disease.

Authors:  N B Farber; J W Newcomer; J W Olney
Journal:  Prog Brain Res       Date:  1998       Impact factor: 2.453

4.  A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.

Authors:  Carlos A Zarate; Jaskaran B Singh; Paul J Carlson; Nancy E Brutsche; Rezvan Ameli; David A Luckenbaugh; Dennis S Charney; Husseini K Manji
Journal:  Arch Gen Psychiatry       Date:  2006-08

5.  Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression.

Authors:  G Rajkowska; J J Miguel-Hidalgo; J Wei; G Dilley; S D Pittman; H Y Meltzer; J C Overholser; B L Roth; C A Stockmeier
Journal:  Biol Psychiatry       Date:  1999-05-01       Impact factor: 13.382

Review 6.  Functional neuroimaging studies of depression: the anatomy of melancholia.

Authors:  W C Drevets
Journal:  Annu Rev Med       Date:  1998       Impact factor: 13.739

7.  Prefrontal cortical network activity: Opposite effects of psychedelic hallucinogens and D1/D5 dopamine receptor activation.

Authors:  E K Lambe; G K Aghajanian
Journal:  Neuroscience       Date:  2007-02-09       Impact factor: 3.590

Review 8.  mTOR signaling: at the crossroads of plasticity, memory and disease.

Authors:  Charles A Hoeffer; Eric Klann
Journal:  Trends Neurosci       Date:  2009-12-04       Impact factor: 13.837

9.  Stress blunts serotonin- and hypocretin-evoked EPSCs in prefrontal cortex: role of corticosterone-mediated apical dendritic atrophy.

Authors:  Rong-Jian Liu; George K Aghajanian
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-02       Impact factor: 11.205

10.  The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R).

Authors:  Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Doreen Koretz; Kathleen R Merikangas; A John Rush; Ellen E Walters; Philip S Wang
Journal:  JAMA       Date:  2003-06-18       Impact factor: 56.272

View more
  1027 in total

1.  ¹H-[¹³C]-nuclear magnetic resonance spectroscopy measures of ketamine's effect on amino acid neurotransmitter metabolism.

Authors:  Golam M I Chowdhury; Kevin L Behar; William Cho; Monique A Thomas; Douglas L Rothman; Gerard Sanacora
Journal:  Biol Psychiatry       Date:  2011-12-09       Impact factor: 13.382

2.  The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder.

Authors:  Courtney S Jernigan; Dharmendra B Goswami; Mark C Austin; Abiye H Iyo; Agata Chandran; Craig A Stockmeier; Beata Karolewicz
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2011-05-23       Impact factor: 5.067

Review 3.  Networking in autism: leveraging genetic, biomarker and model system findings in the search for new treatments.

Authors:  Jeremy Veenstra-VanderWeele; Randy D Blakely
Journal:  Neuropsychopharmacology       Date:  2011-09-21       Impact factor: 7.853

4.  A single subanesthetic dose of ketamine relieves depression-like behaviors induced by neuropathic pain in rats.

Authors:  Jing Wang; Yossef Goffer; Duo Xu; David S Tukey; D B Shamir; Sarah E Eberle; Anthony H Zou; Thomas J J Blanck; Edward B Ziff
Journal:  Anesthesiology       Date:  2011-10       Impact factor: 7.892

5.  CD-1 and Balb/cJ mice do not show enduring antidepressant-like effects of ketamine in tests of acute antidepressant efficacy.

Authors:  Anita J Bechtholt-Gompf; Karen L Smith; Catherine S John; Hannah H Kang; William A Carlezon; Bruce M Cohen; Dost Ongür
Journal:  Psychopharmacology (Berl)       Date:  2011-01-28       Impact factor: 4.530

Review 6.  Remodeling of axo-spinous synapses in the pathophysiology and treatment of depression.

Authors:  P Licznerski; R S Duman
Journal:  Neuroscience       Date:  2012-10-02       Impact factor: 3.590

7.  Attenuation of reserpine-induced pain/depression dyad by gentiopicroside through downregulation of GluN2B receptors in the amygdala of mice.

Authors:  Shui-bing Liu; Rong Zhao; Xu-sheng Li; Hong-ju Guo; Zhen Tian; Nan Zhang; Guo-dong Gao; Ming-gao Zhao
Journal:  Neuromolecular Med       Date:  2014-03-01       Impact factor: 3.843

8.  Calcium-permeable AMPA receptors in the nucleus accumbens regulate depression-like behaviors in the chronic neuropathic pain state.

Authors:  Yossef Goffer; Duo Xu; Sarah E Eberle; James D'amour; Michelle Lee; David Tukey; Robert C Froemke; Edward B Ziff; Jing Wang
Journal:  J Neurosci       Date:  2013-11-27       Impact factor: 6.167

Review 9.  Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant.

Authors:  Saurabh S Kokane; Ross J Armant; Carlos A Bolaños-Guzmán; Linda I Perrotti
Journal:  Behav Brain Res       Date:  2020-02-13       Impact factor: 3.332

10.  Role of Neuronal VEGF Signaling in the Prefrontal Cortex in the Rapid Antidepressant Effects of Ketamine.

Authors:  Satoshi Deyama; Eunyoung Bang; Eric S Wohleb; Xiao-Yuan Li; Taro Kato; Danielle M Gerhard; Sophie Dutheil; Jason M Dwyer; Seth R Taylor; Marina R Picciotto; Ronald S Duman
Journal:  Am J Psychiatry       Date:  2019-01-04       Impact factor: 18.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.